Search Results - "LAKTIONOV, K. K"

Comparisons of microRNA patterns in plasma before and after tumor removal reveal new biomarkers of lung squamous cell carcinoma by Aushev, Vasily N, Zborovskaya, Irina B, Laktionov, Konstantin K, Girard, Nicolas, Cros, Marie-Pierre, Herceg, Zdenko, Krutovskikh, Vladimir

“…Lung cancer is the major human malignancy, accounting for 30% of all cancer-related deaths worldwide. Poor survival of lung cancer patients, together with late…”
Get full text

Use of selpercatinib in a patient with RET-mutated non-small cell lung cancer: case report by Kazakov, A. M., Laktionov, K. K., Vorobyeva, V. O., Sarantseva, K. A.

“…Background . The use of the modern targeted drugs in patients with non-small-cell lung cancer (NSCLC) with certain somatic alterations (genetic alterations in…”
Get full text

KRAS-mutated non-small cell lung cancer: new therapy strategies by Laktionov, K. K., Sarantseva, K. A., Nelyubina, L. A., Gamayunov, S. V., Kolesnikova, E. A., Gordiev, M. G.

“…Lung cancer remains one of the most dangerous and most common cancers, requiring constant improvement of diagnostic and treatment methods. The genetic…”
Get full text

Nivolumab with Ipilimumab in the treatment of refractory hepatocellular carcinoma by Khagazheeva, M. N., Dzhanyan, I. A., Breder, V. V., Laktionov, K. K.

“…HCC is considered refractory when it comes to progression during treatment with TKIs (sorafenib, lenvatinib). The combined immunotherapy of nivolumab with…”
Get full text

Adjuvant immunotherapy of operable non-small cell lung cancer: achievements and treatment prospects by Denisova, E. S., Laktionov, K. K., Ardzinba, M. A., Reutova, E. V.

“…Lung cancer is one of the most common malignant tumors with the highest mortality, with about 85% of cases of the disease being non-small cell lung cancer. To…”
Get full text

Efficacy of lorlatinib in the treatment of ALK-positive non-small cell lung cancer patients with progression on crizotinib: personal experience by Laktionov, K. K., Reutova, E. V., Kruteleva, S. Yu, Antonova, E. Yu

“…Introduction . Lorlatinib is a  third generation ALK tyrosine kinase inhibitor. Back in  2018, the  drug underwent accelerated FDA approval and was recommended…”
Get full text

Evaluation and modifcation of lung immune prognostic index in patients with metastatic NSCLC treated by immunotherapy by Yudin, D. I., Laktionov, K. K., Sarantseva, K. A., Barbolina, T. D., Djanyan, I. A.

“…Aim of the study : to evaluate prognostic value of baseline lung immune prognostic index (LIPI) and its modification (mLIPI) for metastatic non-small cell lung…”
Get full text

Second-line treatment of hepatocellular carcinoma: from theory to practical issues by Breder, V. V., Laktionov, K. K.

“…Hepatocellular carcinoma (HCC) is the most frequent primary liver cancer with unmet needs of effective medications. Lenvatinib – a new oral multikinase…”
Get full text

Рembrolizumab as second line therapy for hepatocellular patient by Dzhanyan, I. A., Breder, V. V., Borisova, O. I., Laktionov, K. K.

“…The optimal hepatocellular cancer (HCC) therapy remains a challenge. Due to checkpoint inhibitors patients with intolerance to the targeted therapy and or…”
Get full text

Three-year results of application of nivolumab in patients with non-small cell lung cancer in clinical practice of the N.N. Blokhin Russian Cancer Research Center by Laktionov, K. K., Sarantseva, K. A., Yudin, D. I., Breder, V. V., Reutova, E. V., Laktionov, K. P.

“…Non-small cell lung cancer (NSCLC) is the leading cause of death from cancer worldwide. Despite the success over recent years in the treatment of NSCLC it has…”
Get full text

Ceritinib in the treatment of ALK-positive patients with nonsmall-cell lung cancer by Laktionov, K. K., Reutova, E. V.

“…Ceritinib is the second ALK tyrosine kinase inhibitor after crizotinib, registered in the Russian Federation for the treatment of ALKpositive patients with…”
Get full text

Long-term disease control in a patient with ALK-positive non-small cell lung cancer by Berezina, G. I., Laktionov, K. K., Reutova, E. V., Ardzinba, M. S., Borisova, T. N., Utkina, V. L.

“…Non-small cell lung cancer is a very heterogeneous group of diseases. When choosing an effective patient management strategy, an oncologist focuses on the…”
Get full text

Mutation in the kras gene as a predictor of the effectiveness of immunotherapy for non-small cell lung cancer by Laktionov, K. K., Kazakov, A. M., Sarantseva, K. A., Scherbo, D. S., Koval, A. P.

“…The purpose of the study: to conduct a systematic literature review on the effectiveness and feasibility of using information on the presence of KRAS gene…”
Get full text

Five-year results of nivolumab for the treatment of non-small cell lung cancer in clinical practice of the N.N. Blokhin Russian Cancer Research Center by Yudin, D. I., Laktionov, K. K., Sarantseva, K. A., Breder, V. V., Ardzinba, M. S., Reutova, E. V., Borisova, O. I.

“…Introduction . Lung cancer remains the one of the most common and fatal cancers in the world. For a long time, chemotherapy was the only treatment option…”
Get full text

Immunotherapy for hepatocellular cancer: beginning and future perspectives by Kazantseva, M. A., Breder, V. V., Laktionov, K. K.

“…Hepatocellular cancer (HCC) is a significant problem of modern Oncology. Until recently, sorafenib was the only drug in the treatment of locally advanced and…”
Get full text

A clinical case of 3-year highly efficient pembrolizamable therapy of metasatic lung adenocarcinoma by K. K. Laktionov, D. I. Yudin, K. A. Sarantseva, K. P. Laktionov, V. V. Breder, E. V. Reutova

“…Immunotherapy presents a new promising approach to the treatment of disseminated lung cancer. Pemriblisumab (Kitruda®) is one of the antiPD-1 drugs registered…”
Get full text

A preliminary results of integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small-cell-lung cancer harboring EGFR mutation by Laktionov, K. K., Yudin, D. I., Breder, V. V., Reutova, E. V., Laktionov, K. P., Marinov, D. T., Peregudov, D. A., Ardzinba, M. S.

“…In the open prospective non-randomized single-center study we recruited patients with advanced NSCLC harboring EGFR mutations. Initially there were two months…”
Get full text

Design of targeted next-generation sequencing (NGS) of circulating tumour DNA (ctDNA): towards overcoming DNA by Mileyko, V., Ivanov, M., Ignatova, E., Reznik, A., Laktionov, K., Brede, V., Baranova, A.

Get full text

Clinical case of use of osimertinib in a patient with disseminated EGFR-mutated non-small cell lung cancer in the first-line therapy by Sarantseva, K. A., Laktionov, K. K., Reutova, E. V., Yudin, D. I., Breder, V. V.

“…Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR) that has been approved for the treatment of…”
Get full text

Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies by Passaro, Antonio, de Marinis, Filippo, Tu, Hai-Yan, Laktionov, Konstantin K., Feng, Jifeng, Poltoratskiy, Artem, Zhao, Jun, Tan, Eng Huat, Gottfried, Maya, Lee, Victor, Kowalski, Dariusz, Yang, Cheng Ta, Srinivasa, BJ, Clementi, Laura, Jalikop, Tejaswini, Huang, Dennis Chin Lun, Cseh, Agnieszka, Park, Keunchil, Wu, Yi-Long

“…Background Afatinib is approved for first-line treatment of patients with epidermal growth factor receptor mutation-positive ( EGFR m+) non-small-cell lung…”
Get full text